![]() ![]() The FreeStyle Libre flash glucose monitoring system includes a sensor, which is applied to the back of the upper arm for up to 14 days, paired with a reader or compatible smartphone app 8 that displays glucose readings. People with type 2 diabetes can only get the product reimbursed if they meet certain criteria, such as using insulin several times a day or having poorly controlled glucose levels. 9 Currently, in most European countries, the FreeStyle Libre system is reimbursed for all people with type 1 diabetes. The results from this latest study add to a growing body of evidence that has shown the effectiveness of the FreeStyle Libre system in reducing hospitalisations in people with type 1 and type 2 diabetes on multiple daily injections of insulin. This will help them catch rapidly changing glucose levels and allow them to make adjustments to their lifestyle or medications with much more confidence." "Our goal is to make diabetes care easier, which is why we offer solutions where people can check their actual glucose values and trends anytime 7 on their smartphone or reader. Although the switch is often necessary to manage glucose levels, it can be stressful to inject insulin, which comes with associated risks," said Dr Alexander Seibold, senior medical director in Abbott’s diabetes care division. "Moving from oral medications to insulin therapy can have a big impact on people with type 2 diabetes, both mentally and physically. This is especially relevant for older people, where hypoglycaemia is associated with a significantly increased risk of falls, fractures, dementia, and death. 3,4,5 The RELIEF study suggests that reducing the incidence of hypoglycaemia and DKA may improve adherence and help people with diabetes achieve their glycaemic targets. This fear is a barrier to intensifying treatment and impacts a patient’s willingness to follow the basal insulin therapy as prescribed by their doctor. The fear of hypoglycaemia affects both people with type 2 diabetes and their doctors. However, studies show that people with type 2 diabetes who start basal insulin therapy are three times more likely to experience severe hypoglycaemia. When oral medications are no longer sufficient to regulate glucose levels, a doctor might change diabetes treatment, starting with once-a-day (basal) insulin therapy. "The reductions are similar to the results seen among the larger cohort of people with type 2 diabetes who were receiving multiple daily injections, suggesting that FreeStyle Libre technology therapy should be proposed as part of individualised care for patients with type 2 diabetes on basal-only insulin, not just people on intensive insulin therapy." "The results of the RELIEF study highlight the value of the FreeStyle Libre system in reducing serious diabetes-related events and hospitalisations among patients with type 2 diabetes on basal-only therapy," says Professor Jean-Pierre Riveline, Centre Universitaire du Diabète et de ses Complications, Hôpital Lariboisière. Further, the study showed sustained reductions in hospitalisations over a two-year period of FreeStyle Libre system use, regardless of whether the patients were under the care of a diabetes specialist or a general healthcare practitioner. The data also show a 75% reduction in hospitalisations for diabetic ketoacidosis (DKA), a potentially life-threatening condition when glucose levels are too high for too long and ketone levels rise to dangerous levels in the blood, and a 44% reduction in admissions for severe hypoglycaemia (low glucose levels). The retrospective study of the French national health claims database shows that among the 5,933 people with type 2 diabetes who were following a basal-only regimen, the number of ADE-related hospitalisations decreased by 67% after one year of using the FreeStyle Libre system. ![]() MAIDENHEAD., – Abbott today announced new data from the Real World Evidence of FreeStyle Libre (RELIEF) study showing the use of the FreeStyle Libre continuous glucose monitoring system (CGM) significantly reduced the rate of hospitalisations due to acute diabetes events (ADEs) for people living with type 2 diabetes on once-daily (basal) insulin therapy.1 These findings were published in the Journal of Diabetes Technology & Therapeutics and presented at the 58th Annual European Association for the Study of Diabetes (EASD) meeting. RELIEF study shows sustained reductions in hospitalisations over a two-year period for people on once-daily insulin therapy who were using the FreeStyle Libre system to monitor glucose levels 1.FreeStyle Libre system can help reduce acute diabetes-related events, such as severe hypoglycaemia and diabetic ketoacidosis, leading to a 67% drop in hospitalisations 1. ![]() New Data Shows That Abbott’s FreeStyle Libre ® System Reduces Diabetes-related Hospitalisations for People with Type 2 Diabetes on Once-daily Insulin Therapy
0 Comments
Leave a Reply. |